莫妥珠单抗单药治疗复发/难治性弥漫性大B细胞淋巴瘤患者有效且可耐受
这项单臂扩展队列研究纳入88例既往接受≥2线治疗的复发/难治性弥漫性大B细胞淋巴瘤患者,评估莫妥珠单抗单药疗效与安全性。总缓解率42.0%(95%CI 31.6-53.1),完全缓解率23.9%(95%CI 15.4-34.1),完全缓解率对比历史对照20%未达统计学显著(P=.36)。细胞因子释放综合征发生率26.1%,以1-2级为主。
要点
- 总缓解率42.0%,完全缓解率23.9%,完全缓解率对比历史对照20%未达统计学显著(P=.36)。
- 既往接受CAR-T治疗的26例患者完全缓解率为12%。
- 细胞因子释放综合征发生率26.1%,以1-2级为主,主要发生在第1周期。
核心结论
- 莫妥珠单抗在复发/难治性弥漫性大B细胞淋巴瘤患者(包括既往接受CAR-T治疗者)中显示出显著疗效和可控的安全性。
研究设计与样本
- 1期或2期研究中的单臂扩展队列,纳入88例既往接受≥2线治疗的复发/难治性弥漫性大B细胞淋巴瘤患者。
- 莫妥珠单抗静脉给药,第1周期采用阶梯剂量以减轻细胞因子释放综合征:第1周期第1天1 mg,第1周期第8天2 mg,第1周期第15天和第2周期第1天60 mg,第3周期及以后第1天30 mg。
- 不强制住院;完全缓解患者在完成第8周期后结束治疗,部分缓解或疾病稳定患者继续治疗共17个周期。
- 主要终点为完全缓解率(最佳缓解),由独立审查机构评估,对比历史对照完全缓解率20%。
主要发现
- 88例患者中73.9%为原发弥漫性大B细胞淋巴瘤,26.1%为滤泡性淋巴瘤转化;所有患者均接受过蒽环类和抗CD20治疗。
- 总缓解率为42.0%(95%CI 31.6-53.1),完全缓解率为23.9%(95%CI 15.4-34.1)。
- 完全缓解率对比历史对照20%未达统计学显著(P=.36)。
- 中位至首次缓解时间为1.4个月,中位无进展生存期为3.2个月(95%CI 2.2-5.3)。
- 既往接受CAR-T治疗的26例患者完全缓解率为12%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As part of a phase 1 or 2 study, this single-arm expansion cohort established the efficacy and safety of mosunetuzumab monotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) (received ≥2 previous lines of therapy). Intravenous mosunetuzumab was administered with cycle (C) 1 step-up dosing for cytokine release syndrome (CRS) mitigation: C1 day (D) 1: 1 mg; C1D8 2 mg; C1D15 and C2D1: 60 mg; C3 + D1: 30 mg. Hospitalization was not mandatory. Patients with complete response (CR) completed treatment after C8; those with partial response or stable disease continued treatment for a total of 17 cycles. The primary end point was CR rate (best response), assessed against a historical control CR rate (20%) by independent review facility. Eighty-eight patients (73.9% de novo DLBCL; 26.1% transformed follicular lymphoma) were enrolled; all had received previous anthracycline and anti-CD20 therapy. Overall response and CR rates were 42.0% (95% confidence interval [CI], 31.6-53.1) and 23.9% (95% CI, 15.4-34.1), respectively; CR rate did not reach statistical significance vs the historical control (P = .36). Median time to first response was 1.4 months. Median progression-free survival was 3.2 months (95% CI, 2.2-5.3). The CR rate in 26 patients who received previous chimeric antigen receptor T-cell (CAR-T) therapy was 12%. CRS was one of the most common adverse events (26.1% of patients); predominantly grade 1 to 2 and primarily in C1. Four patients (4.5%) discontinued mosunetuzumab owing to adverse events. Mosunetuzumab demonstrated notable efficacy and a manageable safety profile in patients with R/R DLBCL, including those previously treated with CAR-Ts. This trial was registered at www.clinicaltrials.gov as #NCT02500407.
引用
- Bartlett NL, Assouline S, Giri P, et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv. 2023. PMID: 37067952. doi:10.1182/bloodadvances.2022009260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。